J&J In Deal With Catalyst Biosciences To Discover Inflammatory Disease Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
South San Francisco protease engineering firm also plans to enter the clinic in 2009 with an internally developed competitor to Novo Nordisk’s hemophilia drug NovoSeven, Catalyst CEO Usman tells “The Pink Sheet” DAILY.